MCID: CHL065
MIFTS: 64

Cholangiocarcinoma

Categories: Cancer diseases, Liver diseases, Rare diseases

Aliases & Classifications for Cholangiocarcinoma

MalaCards integrated aliases for Cholangiocarcinoma:

Name: Cholangiocarcinoma 58 39 77 26 60 38 56 17 74
Cholangiocarcinoma, Susceptibility to 58 30
Intrahepatic Cholangiocarcinoma 26 74
Extrahepatic Cholangiocarcinoma 26 74
Adult Primary Cholangiocellular Carcinoma 74
Cholangiocarcinoma of Biliary Tract 26
Cholangiocellular Carcinoma 26
Chlc, Susceptibility to 58
Bile Duct Carcinoma 74
Bile Duct Cancer 60
Chlc 58
Cca 60
Cc 26

Characteristics:

Orphanet epidemiological data:

60
cholangiocarcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe); Age of onset: Adult;

Classifications:

Orphanet: 60  
Rare hepatic diseases


External Ids:

OMIM 58 615619
KEGG 38 H00046
MESH via Orphanet 46 D001650 D018281
ICD10 via Orphanet 35 C22.1 C24.0 C24.8 more
UMLS via Orphanet 75 C0206698 C0740277
Orphanet 60 ORPHA70567
MedGen 43 C3810156

Summaries for Cholangiocarcinoma

OMIM : 58 Carcinomas of the biliary tract are aggressive malignancies, with 5-year survival of less than 10%. These carcinomas arise throughout the biliary tree and are anatomically classified as either intrahepatic or extrahepatic cholangiocarcinomas. Gallbladder carcinomas also arise from the biliary tree but have distinct natural histories compared to cholangiocarcinomas, suggesting different underlying tumor biology. Cholangiocarcinoma incidence varies widely between geographic regions, reflecting the impact of different underlying etiologies. In endemic areas, liver fluke infections by O. viverrini and Clonorchis sinensis, both group I carcinogens, represent the major risk factor for cholangiocarcinomas. In nonendemic regions, other risk factors, including choledochal cysts (603003), hepatolithiasis, and primary sclerosing cholangitis (613806), are likely contributors (summary by Chan-on et al., 2013). Overall, the majority of patients lack such identifiable risk factors (summary by Jiao et al., 2013). (615619)

MalaCards based summary : Cholangiocarcinoma, also known as cholangiocarcinoma, susceptibility to, is related to klatskin's tumor and gallbladder cancer, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Cholangiocarcinoma is MIR21 (MicroRNA 21), and among its related pathways/superpathways are MicroRNAs in cancer and miRNA targets in ECM and membrane receptors. The drugs Pancrelipase and Celecoxib have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and lung, and related phenotypes are jaundice and biliary tract neoplasm

Genetics Home Reference : 26 Cholangiocarcinoma is a group of cancers that begin in the bile ducts. Bile ducts are branched tubes that connect the liver and gallbladder to the small intestine. They carry bile, which is a fluid that helps the body digest the fats in food. Bile is produced in the liver and stored in the gallbladder before being released in the small intestine after a person eats.

Wikipedia : 77 Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts.... more...

Related Diseases for Cholangiocarcinoma

Diseases related to Cholangiocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 589)
# Related Disease Score Top Affiliating Genes
1 klatskin's tumor 34.0 MALAT1 MIR373
2 gallbladder cancer 31.1 AFAP1-AS1 H19 MALAT1
3 kidney cancer 30.4 H19 MALAT1 MIR141 MIR200B MIR21
4 pancreatic ductal adenocarcinoma 30.3 AFAP1-AS1 H19 MALAT1 MIR141 MIR148A MIR21
5 renal cell carcinoma, nonpapillary 30.2 H19 MALAT1 MIR141 PANDAR
6 myeloma, multiple 30.2 H19 MALAT1 PCAT1
7 ovarian epithelial cancer 30.2 H19 HULC MALAT1
8 laryngeal squamous cell carcinoma 30.2 H19 MALAT1 MIR21 NEAT1
9 glioblastoma 30.1 H19 MALAT1 MIR21 PCAT1
10 small cell cancer of the lung 30.1 CCAT2 MALAT1 MIR21
11 tongue squamous cell carcinoma 30.1 AFAP1-AS1 MALAT1 MIR21
12 pancreatic cancer 30.0 AFAP1-AS1 H19 HULC MALAT1 MIR148A MIR21
13 squamous cell carcinoma 30.0 CCAT2 H19 MALAT1 NEAT1 PCAT1 SOX2-OT
14 hepatocellular carcinoma 29.9 AFAP1-AS1 CCAT2 H19 HULC MALAT1 MIR141
15 lung cancer susceptibility 3 29.8 AFAP1-AS1 H19 MALAT1 MIR200B
16 thyroid cancer 29.8 AFAP1-AS1 H19 MALAT1 NEAT1 PANDAR
17 oral squamous cell carcinoma 29.8 CCAT2 H19 MALAT1 MIR200B MIR204 MIR21
18 nasopharyngeal carcinoma 29.8 AFAP1-AS1 H19 HULC MALAT1 NEAT1
19 melanoma 29.7 H19 MALAT1 MIR141 MIR200B MIR204 SOX2-OT
20 cervical cancer 29.7 CCAT2 H19 HULC MALAT1 MIR21 NEAT1
21 leukemia, acute myeloid 29.6 MALAT1 MIR204 MIR21 MIR320A
22 diffuse large b-cell lymphoma 29.6 HULC MIR21 MIR320A PANDAR
23 clear cell renal cell carcinoma 29.4 CCAT2 MALAT1 MIR21 MIR320A PANDAR SPRY4-IT1
24 ovarian cancer 29.4 AFAP1-AS1 CCAT2 H19 MALAT1 MIR141 MIR152
25 gastric cancer 29.3 AFAP1-AS1 CCAT2 H19 HULC MALAT1 MIR141
26 bladder cancer 29.3 CCAT2 H19 HULC MALAT1 MIR21 PANDAR
27 osteogenic sarcoma 29.3 CCAT2 H19 HULC MALAT1 NEAT1 PANDAR
28 prostate cancer 29.2 CCAT2 H19 HULC MALAT1 MIR141 MIR148A
29 colorectal cancer 29.0 AFAP1-AS1 CCAT2 H19 HULC MALAT1 MIR141
30 breast cancer 28.6 CCAT2 H19 MALAT1 MIR141 MIR148A MIR152
31 lung cancer 28.4 AFAP1-AS1 CCAT2 H19 MALAT1 MIR141 MIR148A
32 intrahepatic cholangiocarcinoma 12.7
33 arthrogryposis, distal, type 9 12.3
34 combined hepatocellular carcinoma and cholangiocarcinoma 12.3
35 sarcomatous intrahepatic cholangiocarcinoma 12.3
36 mucinous intrahepatic cholangiocarcinoma 12.3
37 signet ring cell intrahepatic cholangiocarcinoma 12.1
38 epilepsy occipital calcifications 11.6
39 clonorchiasis 11.6
40 bile duct cancer 11.6
41 biliary tract cancer 11.6
42 cholangitis, primary sclerosing 11.5
43 opisthorchiasis 11.5
44 acrocallosal syndrome 11.4
45 central cord syndrome 11.3
46 familial calcium pyrophosphate deposition 11.3
47 cholangitis 10.8
48 sclerosing cholangitis 10.7
49 hepatitis 10.6
50 ovarian serous carcinoma 10.5 MIR141 MIR21

Graphical network of the top 20 diseases related to Cholangiocarcinoma:



Diseases related to Cholangiocarcinoma

Symptoms & Phenotypes for Cholangiocarcinoma

Human phenotypes related to Cholangiocarcinoma:

60 33 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 jaundice 60 33 hallmark (90%) Very frequent (99-80%) HP:0000952
2 biliary tract neoplasm 60 33 hallmark (90%) Very frequent (99-80%) HP:0100574
3 acholic stools 60 33 hallmark (90%) Very frequent (99-80%) HP:0011985
4 fatigue 60 33 frequent (33%) Frequent (79-30%) HP:0012378
5 pruritus 60 33 frequent (33%) Frequent (79-30%) HP:0000989
6 fever 60 33 occasional (7.5%) Occasional (29-5%) HP:0001945
7 abdominal pain 60 33 occasional (7.5%) Occasional (29-5%) HP:0002027
8 anorexia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002039
9 cholangiocarcinoma 33 HP:0030153

Clinical features from OMIM:

615619

UMLS symptoms related to Cholangiocarcinoma:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas, malaise

Drugs & Therapeutics for Cholangiocarcinoma

Drugs for Cholangiocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 338)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 53608-75-6
2
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
3
Desflurane Approved Phase 4,Not Applicable 57041-67-5 42113
4
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
5
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
6
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
7
Etomidate Approved Phase 4 33125-97-2 667484 36339
8
Meperidine Approved Phase 4 57-42-1 4058
9
Bilirubin Phase 4,Not Applicable 635-65-4, 69853-43-6 21252250 5280352
10 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
12 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2
13 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
14 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
15 Cyclooxygenase 2 Inhibitors Phase 4
16 pancreatin Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2
18 Cyclooxygenase Inhibitors Phase 4
19 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 1,Phase 2
20 arginine Phase 4
21 Omega 3 Fatty Acid Phase 4
22 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
23 Central Nervous System Depressants Phase 4,Phase 3,Not Applicable
24 Platelet Aggregation Inhibitors Phase 4
25 Anesthetics, General Phase 4,Phase 3,Not Applicable
26 Anesthetics, Inhalation Phase 4,Not Applicable
27 Anesthetics Phase 4,Phase 3,Not Applicable
28 Cola Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
29
Bismuth Phase 4,Phase 3 7440-69-9 105143 16682734
30 GABA Modulators Phase 4,Not Applicable
31 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Hypnotics and Sedatives Phase 4,Not Applicable
33 GABA Agents Phase 4,Not Applicable
34 Anti-Anxiety Agents Phase 4,Phase 3
35 Narcotics Phase 4,Phase 3,Not Applicable
36 Analgesics, Opioid Phase 4,Phase 3,Not Applicable
37 Adjuvants, Anesthesia Phase 4,Phase 3
38 Psychotropic Drugs Phase 4,Phase 3
39 Anesthetics, Intravenous Phase 4,Phase 3,Not Applicable
40 Tranquilizing Agents Phase 4,Phase 3
41 Ulipristal acetate Phase 4 126784-99-4
42
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
43
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
44
Trioxsalen Approved Phase 2, Phase 3,Phase 3,Not Applicable 3902-71-4 5585
45
Fluorouracil Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 51-21-8 3385
46
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 143 6006
47
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 68538-85-2
48
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
49
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3 128-13-2 31401
50
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345

Interventional clinical trials:

(show top 50) (show all 511)
# Name Status NCT ID Phase Drugs
1 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent Unknown status NCT00746538 Phase 4
2 Preoperative Biliary Drainage for Resectable Hilar Cholangiocarcinoma Unknown status NCT00797121 Phase 4
3 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
4 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
5 Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
6 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
7 Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture Unknown status NCT01125865 Phase 4
8 Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Hilar Cholangiocarcinoma Completed NCT00721175 Phase 4
9 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
10 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
11 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
12 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
13 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
14 Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma Unknown status NCT02108145 Phase 2, Phase 3
15 Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma Unknown status NCT02548195 Phase 3 oxaliplatin and gemcitabine;capecitabine
16 Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma Unknown status NCT01739465 Phase 2, Phase 3
17 Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma Unknown status NCT01755013 Phase 2, Phase 3
18 Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures Unknown status NCT00653978 Phase 3
19 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Unknown status NCT02798510 Phase 3 capecitabine;gemcitabine
20 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
21 S-1 and Photodynamic Therapy in Cholangiocarcinoma Completed NCT00869635 Phase 3 S-1 Chemotherapy
22 Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
23 Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery Completed NCT00513539 Phase 3 porfimer sodium
24 Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
25 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
26 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
27 Trial of High-dose Urso in Primary Sclerosing Cholangitis Completed NCT00059202 Phase 2, Phase 3 Ursodeoxycholic Acid
28 Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms Completed NCT01640522 Phase 3
29 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
30 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
31 A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302) Recruiting NCT03656536 Phase 3 Pemigatinib;Gemcitabine;Cisplatin
32 Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations Recruiting NCT03773302 Phase 3 BGJ398;Gemcitabine;Cisplatin
33 Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma Recruiting NCT02773485 Phase 3 Systemic chemotherapy
34 SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma Recruiting NCT02807181 Phase 2, Phase 3 Cisplatin-gemcitabine
35 Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma Recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
36 A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma Recruiting NCT03251443 Phase 3 Apatinib
37 Bortezomib in Intrahepatic Cholangiocellular Carcinoma Recruiting NCT03345303 Phase 3 Bortezomib
38 HAIC Versus Systemic Chemotherapy for Unresectable ICC Recruiting NCT03771846 Phase 3 gemcitabine, oxaliplatin , fluorouracil, and leucovorin;gemcitabine and oxaliplatin
39 Treatment of Advanced Intrahepatic Cholangiocarcinoma Recruiting NCT03940378 Phase 3 Levamisole Hydrochloride;Anlotinib Hydrochloride Capsules
40 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
41 Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours Recruiting NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
42 Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
43 Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
44 Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy Recruiting NCT02853474 Phase 3
45 Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L Recruiting NCT02232490 Phase 3
46 Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma Active, not recruiting NCT02482454 Phase 2, Phase 3
47 Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) Active, not recruiting NCT02989857 Phase 3 AG-120;AG-120 matched placebo
48 Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma Active, not recruiting NCT01470443 Phase 3 Oxaliplatin;Oxaliplatin
49 Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers Active, not recruiting NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
50 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Active, not recruiting NCT02349412 Phase 3

Search NIH Clinical Center for Cholangiocarcinoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Cholangiocarcinoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Cholangiocarcinoma:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Cholangiocarcinoma:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Genetic Tests for Cholangiocarcinoma

Genetic tests related to Cholangiocarcinoma:

# Genetic test Affiliating Genes
1 Cholangiocarcinoma, Susceptibility to 30

Anatomical Context for Cholangiocarcinoma

MalaCards organs/tissues related to Cholangiocarcinoma:

42
Liver, Lymph Node, Lung, T Cells, Prostate, Skin, Kidney

Publications for Cholangiocarcinoma

Articles related to Cholangiocarcinoma:

(show top 50) (show all 4763)
# Title Authors Year
1
Incidence and Significance of GATA3 Positivity in Pancreatic Ductal Adenocarcinoma and Cholangiocarcinoma. ( 31033498 )
2019
2
Concurrent Pancreatic Metastasis From Lung Adenocarcinoma and Primary Cholangiocarcinoma on FDG PET/CT Imaging. ( 30762824 )
2019
3
Successful Secondary Engraftment of Pancreatic Ductal Adenocarcinoma and Cholangiocarcinoma Patient-Derived Xenografts After Previous Failed Primary Engraftment. ( 30273859 )
2019
4
Y90 Clinical Data Update: Cholangiocarcinoma, Neuroendocrine Tumor, Melanoma, and Breast Cancer Metastatic Disease. ( 31079715 )
2019
5
A comprehensive review of omics and host-parasite interplays studies, towards control of Opisthorchis viverrini infection for prevention of cholangiocarcinoma. ( 31100270 )
2019
6
Cholangiographic Tumor Classification for Simple Patient Selection Prior to Hepatopancreatoduodenectomy for Cholangiocarcinoma. ( 31102092 )
2019
7
The role of single-operator cholangioscopy (SpyGlass) in the intraoperative diagnosis of intraductal borders of cholangiocarcinoma proliferation - pilot study. ( 31109166 )
2019
8
Surgery for cholangiocarcinoma. ( 31109167 )
2019
9
The current role of radiotherapy and systemic therapy in the multidisciplinary treatment of cholangiocarcinoma. ( 31109168 )
2019
10
TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. ( 31109923 )
2019
11
Lnc-RMRP is involved in the progression of cholangiocarcinoma by regulating miR-217. ( 31111617 )
2019
12
Cholangiocarcinoma: State-of-the-art knowledge and challenges. ( 31111668 )
2019
13
The Tumor Microenvironment and Immune Milieu of Cholangiocarcinoma. ( 30907492 )
2019
14
Aspirin use and the risk of cholangiocarcinoma. ( 30907952 )
2019
15
Reply: Effects of Aspirin and Non-Steroidal Anti-Inflammatory Drugs on the Risk of Cholangiocarcinoma: A Meta-Analysis. ( 30907969 )
2019
16
Association of Preoperative Platelet-to-Lymphocyte Ratio with Poor Outcome in Patients with Distal Cholangiocarcinoma. ( 30909286 )
2019
17
Corrigendum to "Induction of phosphatase shatterproof 2 by evodiamine suppresses the proliferation and invasion of human cholangiocarcinoma" [Int. J. Biochem. Cell Biol. 108 (2019) 98-110]. ( 30910281 )
2019
18
Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. ( 30910538 )
2019
19
Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching Analysis. ( 30910867 )
2019
20
Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. ( 30914290 )
2019
21
A radiomics approach to predict lymph node metastasis and clinical outcome of intrahepatic cholangiocarcinoma. ( 30915561 )
2019
22
Differentiation of two subtypes of intrahepatic cholangiocarcinoma: imaging approach. ( 30915566 )
2019
23
Asbestos fiber identification in liver from cholangiocarcinoma patients living in an asbestos polluted area: a preliminary study. ( 30915902 )
2019
24
Risk of cholangiocarcinoma in patients undergoing therapeutic endoscopic retrograde cholangiopancreatography or cholecystectomy: A population based study. ( 30918596 )
2019
25
TCF21 inhibits tumor-associated angiogenesis and suppresses the growth of cholangiocarcinoma by targeting PI3K/Akt and ERK signaling. ( 30920845 )
2019
26
Indications for laparoscopic liver resection of mass-forming intrahepatic cholangiocarcinoma. ( 30924307 )
2019
27
Should Utilization of Lymphadenectomy Vary According to Morphologic Subtype of Intrahepatic Cholangiocarcinoma? ( 30927194 )
2019
28
The SIRT2/cMYC Pathway Inhibits Peroxidation-Related Apoptosis In Cholangiocarcinoma Through Metabolic Reprogramming. ( 30933885 )
2019
29
Endoscopic Ultrasonography-Guided Fine Needle Aspiration for Extrahepatic Cholangiocarcinoma: A Safe Tissue Sampling Modality. ( 30934706 )
2019
30
Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients. ( 30935002 )
2019
31
Genetic features associated with 18F-FDG uptake in intrahepatic cholangiocarcinoma. ( 30941318 )
2019
32
Programmed Death-1 Inhibitor for Occupational Intrahepatic Cholangiocarcinoma Caused by Chlorinated Organic Solvents. ( 30945442 )
2019
33
A Study on Radial Margin Status in Resected Perihilar Cholangiocarcinoma. ( 30946074 )
2019
34
Elevation of circular RNA circ_0005230 facilitates cell growth and metastasis via sponging miR-1238 and miR-1299 in cholangiocarcinoma. ( 30946694 )
2019
35
Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma. ( 30949409 )
2019
36
Short- and Long-Term Outcomes of Liver Resection for Intrahepatic Cholangiocarcinoma Associated with the Metabolic Syndrome. ( 30949764 )
2019
37
α7-Nicotinic Acetylcholine Receptor Promotes Cholangiocarcinoma Progression and Epithelial-Mesenchymal Transition Process. ( 30949902 )
2019
38
Comparison of the Clinicopathological Features in Small Bile Duct and Bile Ductular Type Intrahepatic Cholangiocarcinoma. ( 30952758 )
2019
39
A 12-year Recurrence-free Survival After Multidisciplinary Treatment for a Patient With Combined Hepatocellular-Cholangiocarcinoma. ( 30952760 )
2019
40
The Efficacy and Limitations of Postoperative Adjuvant Chemotherapy in Patients With Extrahepatic Cholangiocarcinoma. ( 30952762 )
2019
41
Novel biomarkers distinguishing pancreatic head Cancer from distal cholangiocarcinoma based on proteomic analysis. ( 30953499 )
2019
42
Hepatitis C Virus Infection and Cholangiocarcinoma: An Insight into Epidemiologic Evidences and Hypothetical Mechanisms of Oncogenesis. ( 30953604 )
2019
43
Prognostic relevance of preoperative bilirubin-adjusted serum carbohydrate antigen 19-9 in a multicenter subset analysis of 179 patients with distal cholangiocarcinoma. ( 30956162 )
2019
44
Incidence of Cholangiocarcinoma in the USA from 2001 to 2015: A US Cancer Statistics Analysis of 50 States. ( 30956914 )
2019
45
Relevance of Preoperative Hyperbilirubinemia in Patients Undergoing Hepatobiliary Resection for Hilar Cholangiocarcinoma. ( 30959757 )
2019
46
Combined Treatment of Nonresectable Cholangiocarcinoma Complicated by Obstructive Jaundice. ( 30965145 )
2019
47
LncRNA LINC01061 sponges miR-612 to regulate the oncogenic role of SEMA4D in cholangiocarcinoma. ( 30967271 )
2019
48
Successful resection of intrahepatic cholangiocarcinoma with idiopathic thrombocytopenic purpura using thrombopoietin receptor agonist: a case report. ( 30969381 )
2019
49
Causes of hOCT1-dependent cholangiocarcinoma resistance to sorafenib and sensitization by tumor-selective gene therapy. ( 30972782 )
2019
50
Is exposure to tobacco associated with extrahepatic cholangiocarcinoma epidemics? A retrospective proportional mortality study in China. ( 30975121 )
2019

Variations for Cholangiocarcinoma

Cosmic variations for Cholangiocarcinoma:

9 (show top 50) (show all 1877)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6974042 ZFHX3 biliary tract,bile duct,carcinoma,NS c.6964C>T p.R2322* 16:72795718-72795718 0
2 COSM6957143 ZFHX3 biliary tract,bile duct,carcinoma,NS c.3529+1G>A p.? 16:72829778-72829778 0
3 COSM6928728 YAP1 biliary tract,bile duct,carcinoma,NS c.434C>G p.T145S 11:102114256-102114256 0
4 COSM6986174 XPO1 biliary tract,bile duct,carcinoma,NS c.273G>T p.W91C 2:61522639-61522639 0
5 COSM6985358 XPO1 biliary tract,bile duct,carcinoma,NS c.338C>T p.T113M 2:61502274-61502274 0
6 COSM6975271 XPO1 biliary tract,bile duct,carcinoma,NS c.729G>T p.E243D 2:61498703-61498703 0
7 COSM968394 TSC2 biliary tract,bile duct,carcinoma,NS c.1819G>A p.A607T 16:2070558-2070558 0
8 COSM6939562 TSC2 biliary tract,bile duct,carcinoma,NS c.1783C>T p.Q595* 16:2070522-2070522 0
9 COSM6923580 TSC1 biliary tract,bile duct,carcinoma,NS c.2551C>T p.Q851* 9:132900789-132900789 0
10 COSM4172016 TSC1 biliary tract,bile duct,carcinoma,NS c.737+1G>A p.? 9:132921362-132921362 0
11 COSM308173 TRIM28 biliary tract,bile duct,carcinoma,NS c.1475G>T p.R492L 19:58549053-58549053 0
12 COSM44463 TP53 biliary tract,bile duct,carcinoma,NS c.848G>T p.R283L 17:7673772-7673772 0
13 COSM10660 TP53 biliary tract,bile duct,carcinoma,NS c.818G>A p.R273H 17:7673802-7673802 0
14 COSM44745 TP53 biliary tract,bile duct,carcinoma,NS c.410T>A p.L137Q 17:7675202-7675202 0
15 COSM10662 TP53 biliary tract,bile duct,carcinoma,NS c.743G>A p.R248Q 17:7674220-7674220 0
16 COSM10687 TP53 biliary tract,bile duct,carcinoma,NS c.527G>A p.C176Y 17:7675085-7675085 0
17 COSM10731 TP53 biliary tract,bile duct,carcinoma,NS c.707A>G p.Y236C 17:7674256-7674256 0
18 COSM11196 TP53 biliary tract,bile duct,carcinoma,NS c.734G>T p.G245V 17:7674229-7674229 0
19 COSM43778 TP53 biliary tract,bile duct,carcinoma,NS c.713G>T p.C238F 17:7674250-7674250 0
20 COSM44309 TP53 biliary tract,bile duct,carcinoma,NS c.440T>G p.V147G 17:7675172-7675172 0
21 COSM44426 TP53 biliary tract,bile duct,carcinoma,NS c.568C>G p.P190A 17:7674963-7674963 0
22 COSM11073 TP53 biliary tract,bile duct,carcinoma,NS c.1024C>T p.R342* 17:7670685-7670685 0
23 COSM10648 TP53 biliary tract,bile duct,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 0
24 COSM11516 TP53 biliary tract,bile duct,carcinoma,NS c.841G>T p.D281Y 17:7673779-7673779 0
25 COSM43751 TP53 biliary tract,bile duct,carcinoma,NS c.673-1G>A p.? 17:7674291-7674291 0
26 COSM44240 TP53 biliary tract,bile duct,carcinoma,NS c.514G>T p.V172F 17:7675098-7675098 0
27 COSM44918 TP53 biliary tract,bile duct,carcinoma,NS c.844C>A p.R282R 17:7673776-7673776 0
28 COSM10812 TP53 biliary tract,bile duct,carcinoma,NS c.722C>T p.S241F 17:7674241-7674241 0
29 COSM10935 TP53 biliary tract,bile duct,carcinoma,NS c.722C>A p.S241Y 17:7674241-7674241 0
30 COSM43635 TP53 biliary tract,bile duct,carcinoma,NS c.536A>T p.H179L 17:7675076-7675076 0
31 COSM44151 TP53 biliary tract,bile duct,carcinoma,NS c.535C>A p.H179N 17:7675077-7675077 0
32 COSM44192 TP53 biliary tract,bile duct,carcinoma,NS c.272G>A p.W91* 17:7676097-7676097 0
33 COSM43836 TP53 biliary tract,bile duct,carcinoma,NS c.475G>C p.A159P 17:7675137-7675137 0
34 COSM10742 TP53 biliary tract,bile duct,carcinoma,NS c.578A>G p.H193R 17:7674953-7674953 0
35 COSM10727 TP53 biliary tract,bile duct,carcinoma,NS c.438G>A p.W146* 17:7675174-7675174 0
36 COSM43779 TP53 biliary tract,bile duct,carcinoma,NS c.589G>A p.V197M 17:7674942-7674942 0
37 COSM44786 TP53 biliary tract,bile duct,carcinoma,NS c.694A>C p.I232L 17:7674269-7674269 0
38 COSM1522202 TP53 biliary tract,bile duct,carcinoma,NS c.1051A>T p.K351* 17:7670658-7670658 0
39 COSM44117 TP53 biliary tract,bile duct,carcinoma,NS c.775G>A p.D259N 17:7674188-7674188 0
40 COSM45679 TP53 biliary tract,bile duct,carcinoma,NS c.868C>T p.R290C 17:7673752-7673752 0
41 COSM10690 TP53 biliary tract,bile duct,carcinoma,NS c.473G>A p.R158H 17:7675139-7675139 0
42 COSM11090 TP53 biliary tract,bile duct,carcinoma,NS c.541C>T p.R181C 17:7675071-7675071 0
43 COSM6081949 TP53 biliary tract,bile duct,carcinoma,NS c.1060C>T p.Q354* 17:7670649-7670649 0
44 COSM6917440 TP53 biliary tract,bile duct,carcinoma,NS c.736A>C p.M246L 17:7674227-7674227 0
45 COSM10645 TP53 biliary tract,bile duct,carcinoma,NS c.527G>T p.C176F 17:7675085-7675085 0
46 COSM10656 TP53 biliary tract,bile duct,carcinoma,NS c.742C>T p.R248W 17:7674221-7674221 0
47 COSM10714 TP53 biliary tract,bile duct,carcinoma,NS c.473G>T p.R158L 17:7675139-7675139 0
48 COSM11071 TP53 biliary tract,bile duct,carcinoma,NS c.1009C>T p.R337C 17:7670700-7670700 0
49 COSM10749 TP53 biliary tract,bile duct,carcinoma,NS c.830G>T p.C277F 17:7673790-7673790 0
50 COSM10768 TP53 biliary tract,bile duct,carcinoma,NS c.535C>T p.H179Y 17:7675077-7675077 0

Copy number variations for Cholangiocarcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 111150 17 35097918 35138441 Copy number ERBB2 Cholangiocarcinoma
2 118016 17 7512444 7519279 Copy number P53 Cholangiocarcinoma
3 159441 21 42600000 48129895 Amplification TFF1 Cholangiocarcinoma
4 159442 21 42600000 48129895 Amplification TFF2 Cholangiocarcinoma
5 159443 21 42600000 48129895 Amplification TFF3 Cholangiocarcinoma

Expression for Cholangiocarcinoma

Search GEO for disease gene expression data for Cholangiocarcinoma.

Pathways for Cholangiocarcinoma

Pathways related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.5 MIR141 MIR152 MIR200B MIR21 MIR373
2 10.59 MIR141 MIR200B

GO Terms for Cholangiocarcinoma

Cellular components related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 MIR141 MIR148A MIR152 MIR204 MIR21 MIR320A
2 micro-ribonucleoprotein complex GO:0035068 9.32 H19 MIR141 MIR148A MIR152 MIR200B MIR204

Biological processes related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 miRNA mediated inhibition of translation GO:0035278 9.33 MIR148A MIR204 MIR21
2 gene silencing by miRNA GO:0035195 9.32 H19 MIR141 MIR148A MIR152 MIR200B MIR204
3 negative regulation of blood vessel endothelial cell migration GO:0043537 9.13 MIR152 MIR200B MIR204

Molecular functions related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.17 MIR141 MIR148A MIR152 MIR200B MIR204 MIR21

Sources for Cholangiocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....